– USA, CT – Intensity Therapeutics, Inc. (Nasdaq: INTS), a late-stage clinical biotechnology company, today announced the appointment of Tom Dubin, J.D., MPH, to its Board as Independent Director, effective May 14, 2024.
Tom Dubin will serve as a member of the Audit Committee.
“We are pleased to welcome Tom Dubin to the Intensity Board. As we prepare to enter Phase 3 clinical development with our unique product candidate, INT230-6, we expect that Tom’s deep experience in pharmaceutical business development, regulatory, and commercialization will be invaluable. We believe that Tom’s commitment to patients, focus on achievement and past successes will strengthen Intensity in multiple ways. We look forward to working with him as we continue our path forward with our exciting new cancer treatment approach,” said Founder, Chairman, and CEO, Lewis Bender.
About Thomas Dubin
From 2001 through 2013, Tom Dubin was chief legal officer and a member of the core executive team that grew Alexion Pharmaceuticals from a development-stage company to a member of the S&P 500. At Alexion, Tom Dubin led legal and government affairs, pricing and reimbursement, corporate communications, and other functions. He also held commercial responsibility for the company’s Australasia region. Before Alexion, Tom Dubin served as VP and General Counsel of ChiRex, Inc., an international corporation providing advanced process development services and specialty manufacturing to the pharmaceutical industry. Tom Dubin began his career as a corporate attorney with Cravath, Swaine & Moore in New York City. He is Chair of Cellphire Therapeutics, a Director of Notable Laboratories, a past Director of BioBlast Pharmaceuticals, a member of the advisory board of Mythic Pharmaceuticals, a Director of Norwalk Hospital, and a member of Yale School of Public Health’s Leadership Council.
Tom Dubin received his J.D. from New York University School of Law, his M.P.H. from Yale University, and his B.A. from Amherst College, cum laude.
About Intensity Therapeutics
Intensity Therapeutics is a late-stage clinical biotechnology company that applies novel engineered chemistry to turn “cold” tumors “hot” by enabling its aqueous cytotoxic-containing drug product, INT230-6, to mix and saturate the dense, high-fat pressurized environment of the tumor. As a result of the saturation, Intensity’s clinical trials have demonstrated the ability of INT230-6 to kill tumors and elicit an adaptive immune response within days of injection, representing a novel approach to cancer cell death that holds the potential to shift the treatment paradigm and turn many deadly cancers into chronic diseases. INT230-6 has completed enrollment of over 200 patients in a Phase 1/2 dose escalation trial (NCT03058289) and a Phase 2 randomized control clinical trial in breast cancer (the INVINCIBLE 2 study) (NCT04781725). The Company is initiating a Phase 3 trial in soft tissue sarcoma (the INVINCIBLE 3 study) (NCT06263231), testing INT230-6 as second or third-line monotherapy compared to the standard of care with overall survival as an endpoint. The Company is also planning a Phase 2/3 program in presurgical triple-negative breast cancer testing INT230-6 in combination with standard of care compared to standard of care alone.
SOURCE: https://intensitytherapeutics.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.